1. Home
  2. SKYE vs SURG Comparison

SKYE vs SURG Comparison

Compare SKYE & SURG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$1.18

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Logo SurgePays Inc.

SURG

SurgePays Inc.

N/A

Current Price

$0.14

Market Cap

6.4M

ML Signal

N/A

Company Overview

Basic Information
Metric
SKYE
SURG
Founded
2012
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
6.4M
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
SKYE
SURG
Price
$1.18
$0.14
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $68.00
N/A
AVG Volume (30 Days)
98.4K
★ 3.2M
Earning Date
11-24-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 24.69
EPS
N/A
★ N/A
Revenue
N/A
★ $56,962,920.00
Revenue This Year
N/A
$14.11
Revenue Next Year
N/A
$23.23
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.26
$0.11
52 Week High
$11.68
$2.08

Technical Indicators

Market Signals
Indicator
SKYE
SURG
Relative Strength Index (RSI) 44.62 46.56
Support Level $0.26 $0.14
Resistance Level $1.66 $0.18
Average True Range (ATR) 0.20 0.02
MACD -0.00 -0.00
Stochastic Oscillator 62.05 30.46

Price Performance

Historical Comparison
SKYE
SURG

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About SURG SurgePays Inc.

Surgepays Inc is a wireless and point of sale technology company focused on serving underserved and value-conscious consumers through a combination of retail distribution and digital acquisition channels. It provides mobile connectivity, financial technology services, and transaction processing solutions through an integrated platform that combines wireless services with point of sale software and retail distribution. It enables in-store and online activation of wireless services, prepaid top-ups, and financial transactions, allowing consumers to access essential services in both local and digital environments. Its segments are wireless services or MVNO Telecommunications, platform services or MVNE Enablement Platform (HERO), and wholesale enablement or Comprehensive Platform Services.

Share on Social Networks: